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Abstract
Background and Objective New treatments for haemophilia are under development or entering the market, including extended 
half-life products, designer drugs and gene therapy, thereby increasing treatment options for haemophilia. It is currently 
unknown how people with haemophilia decide whether to switch to a new treatment. Therefore, the objective of this study 
was to explore what factors may play a role when Dutch patients and parents of boys with moderate or severe haemophilia 
make decisions about whether to switch to a different treatment, and how disease and treatment characteristics may affect 
these decisions. This may aid clinical teams in tailored information provision and shared decision making.
Methods We conducted interviews among adults with moderately severe or severe haemophilia and parents of young boys 
with severe haemophilia. We aimed to include participants from a variety of backgrounds in terms of involvement in the 
haemophilia community, age, treatment centre and treatments. Participants were recruited through the Netherlands Hae-
mophilia Society and a haemophilia treatment centre. Semi-structured interviews were recorded and transcribed verbatim. 
Thematic content analysis was used to analyse the data.
Results Twelve people with haemophilia and two mothers of boys with haemophilia were included. In general, participants 
reported to be satisfied with their current treatment. However, they considered ease of use of the medication (fewer injec-
tions, easier handling, alternative administration) an added value of new treatments. Participants were aware of the high cost 
of coagulation factor products and some expressed their concern about the Netherlands Haemophilia Society’s long-term 
willingness to pay for current and novel treatments, especially for increased usage due to high-risk activities. Participants 
also expressed their concerns about the short- and long-term safety of new treatments and believed the effects of gene therapy 
were not yet fully understood. Participants expected their treatment team to inform them when a particular new treatment 
would be suitable for them.
Conclusions With the number of treatment options set to increase, it is important for healthcare providers to be aware of 
how patient experiences shape patients’ decisions about new therapies.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-019-00395 -6) contains 
supplementary material, which is available to authorized users.
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Key Points 
In addition to injection frequency, bleed control and 
infection risk, costs of treatment may play a role in deci-
sions about novel therapies.
People with haemophilia appreciate information about 
new therapies from both the Netherlands Haemophilia 
Society and their treating physician. They expect their 
treatment team to inform them about specific new prod-
ucts that are suitable for them.
1 Introduction
Haemophilia is a rare congenital coagulation disorder caused 
by a deficiency in either factor VIII (haemophilia A) or fac-
tor IX (haemophilia B), affecting 1 in 10,000 live births [1]. 
Haemophilia is classified into severe haemophilia (< 1% of 
normal), moderate haemophilia (1–5% of normal) and mild 
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haemophilia (5–40% of normal) [1, 2]. The lack of coagula-
tion factor VIII or IX causes spontaneous bleeds in patients 
with severe haemophilia, mainly into joints and muscles, 
causing debilitating and painful joint damage [3]. Treat-
ment has evolved from whole blood transfusions prior to 
the 1960s to modern concentrated recombinant factor VIII 
and IX products. The deficient coagulation factor is admin-
istered two to three times a week by an intravenous injec-
tion to prevent bleeds (prophylaxis). Unfortunately, many 
people with haemophilia were infected with human immu-
nodeficiency virus and/or hepatitis C virus through whole 
blood products in the 1980s and early 1990s [1, 4]. In the 
last few years, products with an extended half-life (requiring 
less frequent administration) have become available. The 
availability of treatment has improved the life expectancy 
of people with haemophilia [5] and decreased bleeding rates 
and joint impairment [6].
Despite these advancements [6], a cure for haemophilia is 
not widely available yet and current treatment is still far from 
optimal. According to patients, products could be improved 
for frequency of administration [7], efficacy of coagulation 
products (preventing bleeds) [8], mode of administration [7], 
easier storage [7, 8], fewer side effects (potential transmis-
sion of pathogens, antibodies against infused factor VIII or 
IX) and packaging (size, components of medication, logis-
tics) [7, 8]. Intravenous infusion of coagulation factor may 
pose a problem, especially for young children with delicate 
veins or for older people, for example, owing to an increased 
difficulty in self-administration with increasing age [9].
New treatments are under development or have recently 
been marketed that aim to address the disadvantages men-
tioned above, such as products with an extended half-life, 
gene therapy and products that affect the coagulation cas-
cade through different mechanisms than replacing the absent 
coagulation factor. Some of these products may be admin-
istered subcutaneously and no longer require intravenous 
injections. However, new treatments may have drawbacks 
of their own, including known and unknown risks, as sum-
marised in Table 1 [10–14].
The Netherlands is a small country with high-quality 
healthcare and social security systems. The cost of coagula-
tion factor is covered under public health insurance, with a 
deductible for specialist care. Several factor VIII and factor 
IX products are available to patients and providers. People 
with haemophilia receive care from one of six Dutch Hae-
mophilia Treatment Centers and most people with severe 
haemophilia attend their clinic appointment annually.
It is currently not sufficiently known which factors play 
a role in patients’ decisions about whether switch to a new 
therapy. Previous internet surveys conducted in Australia, 
Canada, USA and Sweden reported that the frequency of 
clotting factor treatment administration [15, 16], efficacy to 
prevent bleeds [15, 16], manufacturer of the product [15] 
and shared decision making [16] were important to patients. 
Finally, a study in Germany, Austria and Switzerland found 
that parents were more hesitant to switch to an extended 
half-life product than patients [8]. However, these question-
naires mostly presented a finite number of factors that may 
play a role in decision making. Questionnaires also provide 
little information on how individuals’ personal backgrounds 
(e.g. age) and their disease and treatment characteristics 
and experiences (e.g. bleed history, experience with self-
administration of coagulation factor, history of blood-borne 
infections) may affect decision making. A better understand-
ing of all factors that may play a role in decisions about 
treatment (both treatment and personal characteristics) will 
help haemophilia care providers provide tailored information 
when making shared decisions on the optimal management 
strategy of haemophilia [17, 18], all of which are elements 
of patient-centred care [19–21]. Therefore, we aimed to 
explore what factors may play a role when Dutch patients 
and parents of boys with moderate or severe haemophilia 
make decisions about whether to switch to a different treat-
ment, and how disease and treatment characteristics may 
affect these decisions.
2  Methods
2.1  Study Design
We conducted a qualitative study among people with haemo-
philia A or B or parents of young boys with haemophilia A 
or B, using interview methods. We aimed to include partici-
pants with varying involvement in the haemophilia commu-
nity, age, and treatment centre, and in the dosing, type and 
frequency of treatment (purposive sampling) [22]. Prior to 
the interviews, topic lists were prepared based on literature 
and clinical experience. These included questions about cur-
rent and novel treatments, the burden of haemophilia, and 
its treatment and involvement in decision making. Interview 
questions were revised iteratively after each interview so that 
new interesting issues that were raised could be explored 
in future interviews [23]. The topic list is included in the 
Electronic Supplementary Material.
2.2  Recruitment and Data Collection
Participants were approached through the Netherlands Hae-
mophilia Society by an advertisement in a private Facebook 
group moderated by the Society and the quarterly e-mail 
newsletter to members. Participants were also approached 
with an invitation letter of the haemophilia outpatient clinic 
of the Amsterdam University Medical Centers, the Nether-
lands, or through word of mouth. After a positive response, 
Patient Perspectives on Novel Haemophilia Treatment
Ta
bl
e 
1 
 O
ve
rv
iew
 of
 ha
em
op
hi
lia
 A
 an
d B
 tr
ea
tm
en
t p
ro
du
cts
 cu
rre
nt
ly
 un
de
r d
ev
elo
pm
en
t o
r m
ar
ke
ted
 re
ce
nt
ly,
 w
ith
 th
eir
 be
ne
fit
s, 
po
ten
tia
l d
isa
dv
an
tag
es
 an
d m
ec
ha
ni
sm
s o
f a
cti
on
 [1
0–
14
]
AA
V 
ad
en
o-
as
so
cia
ted
 vi
ru
s, 
FE
IB
A 
Fa
cto
r E
ig
ht
 In
hi
bi
to
r B
yp
as
sin
g A
cti
vi
ty,
 F
IX
 fa
cto
r I
X,
 F
VI
II
 fa
cto
r V
III
, F
X 
fac
to
r X
, P
EG
 po
lye
th
yl
en
e g
lyc
ol
, T
FP
I t
iss
ue
 fa
cto
r p
ath
wa
y i
nh
ib
ito
r
Ty
pe
 of
 pr
od
uc
t
M
ec
ha
ni
sm
 of
 ac
tio
n
Po
ten
tia
l b
en
efi
ts
Po
ten
tia
l d
isa
dv
an
tag
es
On
 th
e m
ar
ke
t i
n t
he
 N
eth
er
lan
ds
Ex
ten
de
d h
alf
-li
fe
Re
pl
ac
em
en
t (
Fc
-p
ro
tei
n o
r a
lb
um
in
 
fu
sio
n, 
PE
Gy
lat
io
n, 
alb
um
in
 fu
sio
n 
de
cr
ea
se
 cl
ea
ra
nc
e)
Fe
we
r i
nf
us
io
ns
Hi
gh
er
 tr
ou
gh
 le
ve
ls
Fe
we
r p
ea
ks
 fo
r h
ig
h-
ris
k a
cti
vi
tie
s (
e.g
. 
sp
or
ts)
Un
kn
ow
n s
id
e e
ffe
cts
 of
 th
e a
cc
um
ul
a-
tio
n o
f P
EG
s
Ye
s, 
sin
ce
 20
16
No
n-
fac
to
r c
oa
gu
-
lat
io
n r
ep
lac
e-
m
en
t t
he
ra
py
Bi
sp
ec
ifi
c a
nt
ib
od
y t
ha
t l
in
ks
 ac
tiv
ate
d 
FI
X 
an
d F
X,
 m
im
ick
in
g t
he
 fu
nc
tio
n o
f 
FV
III
 (e
m
ici
zu
m
ab
)
Op
tio
n f
or
 pe
rso
ns
 w
ith
 ha
em
op
hi
lia
 A
 
(w
ith
 or
 w
ith
ou
t i
nh
ib
ito
rs)
No
 in
hi
bi
to
r d
ev
elo
pm
en
t a
ga
in
st 
FV
III
Su
bc
ut
an
eo
us
 ad
m
in
ist
ra
tio
ns
Lo
ng
 ha
lf-
lif
e
Ex
ce
lle
nt
 bl
ee
d c
on
tro
l
Lo
ng
-te
rm
 ri
sk
s s
til
l u
nk
no
wn
No
n-
ne
ut
ra
lis
in
g a
nt
ib
od
ies
 ag
ain
st 
em
ici
zu
m
ab
Th
ro
m
bo
tic
 co
m
pl
ica
tio
ns
 (i
f c
om
bi
ne
d 
wi
th
 F
EI
BA
)
Co
st
Ye
s (
fo
r p
ati
en
ts 
wi
th
 in
hi
bi
to
rs 
on
ly
), 
sin
ce
 20
18
Pr
od
uc
ts 
th
at 
re
ba
lan
ce
 th
e 
co
ag
ul
ati
on
 
sc
ale
In
hi
bi
tio
n o
f T
FP
I (
co
nc
izu
m
ab
), 
an
ti-
th
ro
m
bi
n (
fit
us
ira
n)
 or
 ac
tiv
ate
d p
ro
tei
n 
C
No
 in
hi
bi
to
r d
ev
elo
pm
en
t a
ga
in
st 
FV
III
 
or
 F
IX
M
od
e o
f a
dm
in
ist
ra
tio
n
Fr
eq
ue
nc
y o
f a
dm
in
ist
ra
tio
n
Lo
ng
 ha
lf-
lif
e
Th
ro
m
bo
tic
 co
m
pl
ica
tio
ns
 (fi
tu
sir
an
)
No
, p
ha
se
 II
I t
ria
l
Ge
ne
 th
er
ap
y
(A
AV
) v
ira
l v
ec
to
r t
ra
ns
fer
s F
VI
II 
or
 F
IX
 
DN
A 
to
 li
ve
r, 
wh
er
e i
t i
s e
xp
re
ss
ed
Po
ten
tia
l ‘
cu
re
’ f
or
 ha
em
op
hi
lia
, t
ra
ns
-
fo
rm
in
g s
ev
er
e i
nt
o m
ild
 ha
em
op
hi
lia
 
or
 no
rm
ali
ty
No
 ne
ed
 fo
r p
ro
ph
yl
ax
is 
wi
th
 fa
cto
r 
co
nc
en
tra
tes
Ve
cto
r i
ns
er
tio
n i
nt
o h
os
t g
en
om
e
Ca
nc
er
 (n
ev
er
 ob
se
rv
ed
 in
 A
AV
-b
as
ed
 
ge
ne
 th
er
ap
y)
Li
ve
r i
nfl
am
m
ati
on
 (t
ra
ns
am
in
iti
s)
No
, p
ha
se
 II
I t
ria
l (
ha
em
op
hi
lia
 B
) o
r 
ph
as
e I
 (h
ae
m
op
hi
lia
 A
)
 E. C. van Balen et al.
interviewers introduced themselves over the phone and an 
appointment was established.
BB and MLW, undergraduate students in health sciences 
with some experience in interviewing, conducted semi-
structured interviews between March and December 2017 
at the participants’ homes. The number of interviews was 
pre-determined to be 12–14. A sample size of 12–15 is con-
sidered sufficient to understand participants’ experiences in 
thematic content analysis [23]. Interviews lasted between 
37 and 82 min and were audio-recorded and transcribed 
verbatim.
2.3  Analysis
Thematic content analysis [23] was used to analyse the data. 
All interview transcripts were initially coded using open 
coding with the software program MAXQDA version 12 
(http://www.maxqd a.com). Three researchers (EvB, BB, 
MLW) discussed codes and agreed on a coding scheme, 
which was then applied to all transcripts. Codes were organ-
ised into main topics and reorganised into themes that were 
relevant to the research question, creating a thematic map. 
This map consisted of themes related to experiences with 
current and past treatment, reasons for whether to switch to 
new treatment options and sources of information for these 
decisions. Within themes, we looked for differences and 
similarities between participants. The authors EvB, JvdB, 
SG and MJW discussed final codes and themes. Quotes were 
extracted to illustrate aspects of themes using participants’ 
own words.
2.4  Ethics
Exemption from full dossier ethical approval was obtained 
from the Research Ethics Board of the Amsterdam Uni-
versity Medical Centers. All participants provided written 
informed consent.
3  Results
3.1  Participants
Of 14 individuals who participated, 12 had moderate or 
severe haemophilia. Two were mothers of children with 
severe haemophilia (aged 7 and 10 years). The 14 partici-
pants reflected a variety of the Dutch population with moder-
ate and severe haemophilia in terms of age, treatment centre, 
needle fear, human immunodeficiency virus and hepatitis 
C virus infection status, perceived involvement in decision 
making and membership of the Netherlands Haemophilia 
Society (Table 2). Thirteen participants were receiving home 
treatment (12 prophylaxis, one on-demand). One participant 
did not self-infuse but visited the hospital when he had a 
bleed. All used standard half-life recombinant coagulation 
factor products.
The results are described in three themes: (1) current 
treatment, experiences and perspectives, (2) factors related 
to deciding to switch to a new therapy and (3) sources of 
information regarding novel treatments.
3.2  Current Treatment, Experiences 
and Perspectives
Experiences with current treatment were mostly positive, 
but self-administering treatment was sometimes described 
as a challenge. In general, participants reported that cur-
rent coagulation factor treatment was easy to administer, 
safe and effective in preventing bleeds. Younger partici-
pants reported it had always been part of their daily lives. 
However, older participants remembered that in the past, 
treating themselves was more burdensome than currently 
because of the larger volume of past products, the need to 
carefully mix components of the medication and the longer 
time it required to infuse intravenously. They appreciated 
how much easier administration had become. Those tak-
ing prophylaxis all reported that they adjusted their infusion 
schedules depending on their daily activities, but considered 
themselves adherent.
Three individuals in their 60s and 70s (P1, P2 and P8) 
said injecting at home had become more difficult in recent 
years because of scarring of the injection site or reduced 
eyesight. Participants 8 and 13 commented that self-infusing 
could be ‘a hassle’, and participant 8 found ordering, picking 
up and storing the treatment product quite an effort. Two 
participants sometimes experienced slipping of the needle 
from the injection site. One of the mothers said she some-
times felt pressure to perform the venipuncture when her son 
had an acute bleed.
All participants were aware that new treatments had 
recently become available or were under development. 
Despite the challenges they described with their current 
treatment, they said they did not need new products for 
themselves, but welcomed this development.
Many participants were aware of the high costs and tried 
to use their products responsibly. Eight participants (six on 
prophylaxis, two on-demand) spontaneously mentioned the 
current high costs of their coagulation factor products. The 
six participants who were asked about costs were aware 
that their treatment was expensive. Interestingly, six par-
ticipants (three taking on-demand treatment) reported that 
they avoided injections when possible to save costs for the 
healthcare system, against their physician’s advice to take 
their coagulation factor when they needed it.
Participants were grateful that the cost of their coagu-
lation factor was covered by the healthcare system. Some 
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were concerned about a perceived societal trend in which 
patients are increasingly responsible for their own healthcare 
costs. Participant 2, for example, remembered that sufficient 
amounts of coagulation factor were not always available in 
the past:
“It is a concern to me, because I can imagine […] that 
treatment will become scarce again. [The availability 
of] treatment is not a given if costs get out of control. 
We are dependent on the solidarity of society”
Table 2  Participant characteristics
HA haemophilia A, HB haemophilia B, HCV hepatitis C virus, HIV human immunodeficiency virus, IU international units
a Participants’ ages are presented in age groups to protect their privacy
b Participants were asked whether they felt they were involved the decision making about product and dose
Par-
ticipant 
number
Age  groupa, 
years
Severity and type 
of HA
Type of product 
(standard half-
life recombinant 
coagulation fac-
tor concentrate)
Reported needle 
fear
HIV or HCV 
infection
Perceived 
involvement 
in decision 
 makingb
Member of Neth-
erlands Haemo-
philia Society
P1 65–70 Severe HA Prophylaxis, 
500 IU daily
No HCV (cleared) Yes Yes
P2 70–75 Severe HA Prophylaxis, 
1000 IU, 2 
times per week
Yes HCV No Yes
P3 25–30 Severe HB Prophylaxis, 
1000 IU, once 
every 4–5 days
No HCV (cleared) Yes Yes
P4 Child < 12 Severe HA Prophylaxis, 
750 IU, 3 times 
per week
Sometimes None No Yes
P5 65–70 Moderate-severe 
HA
On-demand 
(mild pheno-
type)
No None Yes Yes
P6 Child < 12 Severe HA Prophylaxis, 
500 IU, 3 times 
per week
No None Yes Yes
P7 40–45 Severe HA Prophylaxis, 
2000 IU, every 
other day
No HCV (cleared) Sometimes Yes
P8 60–65 Severe HA Prophylaxis, 
1000 IU, 3 
times per week
No HCV (cleared) No Yes
P9 20–25 Severe HA Prophylaxis, 
1000 IU, 2–3 
times per week 
(but irregular)
No None Yes No
P10 60–65 Moderate-severe 
HA
On-demand 
(mild pheno-
type)
Unknown HCV (cleared) No Yes
P11 55–60 Severe HA On-demand 
(mild pheno-
type)
No HCV (cleared), 
HIV
No No
P12 35–40 Severe HB On-demand 
(mild pheno-
type)
No HCV No No
P13 25–30 Severe HA Prophylaxis, 
1500 IU, every 
other day (but 
irregular)
No None No Yes
P14 55–60 Severe HA Prophylaxis, 
1000 IU daily
No HCV (cleared) No No
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Furthermore, three of the older participants (P1, P2 and 
P8) expressed their concerns about younger patients engag-
ing in physical activities such as skiing, soccer and mountain 
biking because of the costs for society of the increased pro-
phylactic coagulation factor usage. They thought the avail-
ability of haemophilia treatment may ultimately depend on 
society’s willingness to pay for this increased usage. How-
ever, one of the mothers and four other younger participants 
said practising sports should be possible for persons with 
haemophilia provided they were careful and used prophy-
laxis. One young participant wondered about the costs of 
new extended half-life products:
“You would save a lot of injections [with EHL prod-
ucts], and I don’t know whether that would outweigh 
the higher costs of [this] new product. I don’t mind the 
injections, I don’t mind to infuse a bit more often, […] 
I wouldn’t necessarily want to do that [higher cost] to 
society”. (participant 3)
3.3  Factors Related to Deciding to Switch to a New 
Therapy
When asked, eight participants were open to trying new 
treatments (although some felt they did not urgently need 
them). Three younger participants (P9, P12, P13) with few 
bleeding problems (two taking prophylaxis with irregular 
schedules, one on-demand) did not feel the need to switch 
because they were satisfied with their current treatment. 
The two mothers expressed a wait-and-see attitude for 
novel treatments because at the time of their interviews they 
thought new treatments would not be available soon, and 
they did not want to be the first to try a new therapy because 
of potential unknown risks.
Decisions on whether to switch to a new therapy were 
multifactorial and not self-evident. Factors that may play a 
role in these decisions are summarised in Table 3. Facilitat-
ing factors were improved ease of use of medication and bet-
ter efficacy. Barriers were fear of unknown (short and long 
term) safety and efficacy, and not wanting to be a research 
subject if there were risks involved. Below, we highlight 
some factors that shape participants’ treatment decisions and 
describe them in more detail: ease of use of the medication 
and fear of the unknown.
3.3.1  Facilitator: Ease of Use of the Medication
A majority of eight participants (of whom seven had been 
co-infected) mentioned that they preferred to inject less 
frequently. Three young adults (participants P3, P9 and 
P13) who reported no problems with their current injection 
schedules viewed fewer injections as an added value to new 
therapies that they were looking forward to, but they did 
not consider fewer injections to be absolutely necessary for 
them. They each mentioned an example of others for whom 
extended half-life products with lower injection frequency 
would be especially valuable: for children, for a brother who 
was not as adherent or for others who had more bleeds. Par-
ticipant 1 reported looking forward to being able to inject 
every 3 days instead of daily, which he expected to be a 
reality in 5 years. For another older participant (P2) with a 
hepatitis C virus infection in the past, each injection meant 
a presumed infection risk and for this reason he was looking 
forward to any reduction in injection frequency.
Participants 3 and 12 would prefer a cure for haemophilia 
instead of fewer injections, although they said they had few 
bleeding problems. Furthermore, participant 8, who was 
reluctant to switch because of his experiences with hepatitis 
Table 3  Factors that may play a role in making decisions about switching to new therapies
Reason Barrier/facilitator Key points
Ease of use of the medication Facilitator The ease of use of the medication could be improved by:
 Easier to carry, store and mix
 Less frequent injections, or a (perceived) lack of need for injections alto-
gether with a cure
 Alternatives for intravenous injections: other locations for injecting (subcu-
taneous) or alternative administration routes (tablet or nasal spray)
Equally good or better bleed prevention Facilitator A new therapy should:
 Provide protection against bleeds that is at least as good or even better than 
their current therapy
 Have sufficiently high peak and trough levels
Fear of the unknown Barrier Participants were concerned about still undiscovered transmittable patho-
gens and antibody development. For gene therapy, they were concerned 
about long-term safety of the therapy and thought these effects were not 
yet fully understood
Do not want to be a guinea pig/research subject Barrier Participants felt uncomfortable to participate in a trial because of unknown 
risks or being the first to try a new therapy
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C virus treatment in the past, commented that he would only 
switch if the frequency of injections of extended half-life 
products was considerably lower:
“If I had to switch to a different medication, I would 
switch to one with a longer half-life. That would be a 
bit better for me so I have to inject less often. But the 
savings [in half-life] are not that big […], from 14 to 
17 hours. I didn’t think that was very impressive. For 
that reason I have not switched this time.”
Other reasons participants wanted to inject less frequently 
were the effort it required to plan injections and carry and 
store their coagulation factor products. For example, par-
ticipant 12 travelled frequently for work and thought the 
packaging should be easier to carry with him. Participant 
13 proposed alternative locations for his intravenous injec-
tions, such as a finger or a thigh. When asked about their 
recommendations for drug development companies, several 
participants also suggested different administration routes 
such as a tablet, a nasal spray, an ingestible nanotube with 
coagulation factor or a subcutaneous device.
3.3.2  Barrier: Fear of the Unknown
A few participants were concerned about potential risks of 
new coagulation factor products, such as inhibitor devel-
opment and potential undiscovered transmittable patho-
gens. For extended half-life products, participants 8 and 3 
expressed their concerns about having a low trough level for 
a longer time than with standard half-life products, making 
them more vulnerable to bleeds. A young participant (P3) 
was not convinced safety was properly studied. However, he 
and one of the mothers were willing to try an extended half-
life product because they thought they could always return 
to the standard half-life product.
Many participants thought gene therapy was promising, 
but they were also concerned about its long-term safety and 
the risks of adverse effects.
“It’s a virus that you inject in your body, which may 
cause a liver infection, which would have to be inhib-
ited with corticosteroids.[…] On the other hand, it’s 
such a temporary side effect, and if you benefit from 
that the rest of your life …” (participant 3)
An older participant (P2) said he was hesitant to switch 
to a new treatment because he currently used a product that 
was effective in controlling bleeds, and he did not want to 
risk replacing his current treatment for one with uncertain 
effects. He considered the experience of two others with 
haemophilia who had undergone gene therapy as part of a 
trial in his decision:
“I know two guys that participated in a gene therapy 
trial. One was out of luck, he didn’t achieve higher fac-
tor levels. The other one did. Yes, fantastic if it works. 
[But] they don’t know it yet. […] So you have to ask 
yourself … […] it would be a pure gain if it works. On 
the other hand, if you have good treatment, why would 
you change it?” (Participant 2)
When asked, participants often mentioned they wanted to 
be well informed about possible risks and side effects when 
making decisions about new treatments.
3.4  Sources of Information Regarding Novel 
Treatments
Participants reported that their most important source of 
information was their physician or nurse. Six of them (all 
age groups, members and non-members, different percep-
tions of involvement in decision making) said they discussed 
the development of new therapies with their treatment team 
during their clinic appointment and trusted that their physi-
cian would inform them at the time a particular new treat-
ment was suitable for them.
“The doctors are specialists […] and at some point 
they’ll say: ‘hey, we have this new treatment for you’, 
so I’ll say: ‘sure, bring it on!’” (participant 11)
Those who were members of the Netherlands Haemo-
philia Society also expected the society to provide informa-
tion about the types of treatment that are under development. 
Participants regularly received information from this source, 
for example, from annual general meetings, the Netherlands 
Haemophilia Society’s website, Facebook page, annual 
camping weekend and their biannual magazine. Some par-
ticipants were active in the Facebook group and used it to 
exchange experiences with peers. Participant 11, however, 
was not particularly interested in the information provided 
by the Netherlands Haemophilia Society.
A few people also searched for information on the inter-
net. However, participant 14 said it was difficult to know 
what terms to search for and participant 8 said information 
from other countries, with their different care settings, was 
difficult to apply to his own situation.
4  Discussion
In our interview study, we found that people with moder-
ate or severe haemophilia and parents of young boys with 
haemophilia were generally satisfied with their current treat-
ments. They considered different aspects of novel treatments 
important in their treatment decisions, including ease of use 
of the medication, better bleed control and safety. However, 
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some participants shared concerns about unknown risks of 
new therapies. As an additional finding, the financial burden 
of current treatment on the healthcare system appeared to 
be a concern for a few participants because they felt soci-
etal willingness to pay might not be a given in the future. 
Participants wished to receive information about new treat-
ments, including their risks and benefits from the Nether-
lands Haemophilia Society as well as their haemophilia 
treatment team.
Previous studies have identified similar considerations of 
persons with haemophilia as important features of extended 
half-life products [8, 16]. For example, in assessing a series 
of hypothetical treatment scenarios with three treatment 
attributes each (injection interval, participation in physical 
activity, annual risk of bleed), patients and parents of boys 
with haemophilia ranked bleed control as the most important 
[16]. Another questionnaire study about expectations and 
concerns of extended half-life products reported injection 
frequency to be the most important feature of these prod-
ucts [8]. Our study enriched this knowledge by describing 
the reasons for the desire for a lower injection frequency: a 
presumed infection risk, planning injections and not having 
to carry and store treatment products. Interestingly, many 
participants considered themselves adherent even though 
they skipped infusions, and found treatment products with 
a lower injection frequency especially suitable for ‘others’.
An interesting finding is that the societal financial bur-
den of current haemophilia treatment is a concern for some 
participants. Costs of current treatment have been identified 
as an important feature of haemophilia treatment in previ-
ous discrete-choice experiments that aimed to elicit patient 
preferences [24, 25]. Several participants in our study tried 
to save costs for the healthcare system. Older participants 
appeared to be more conservative in allowing people with 
haemophilia to engage in high-risk activities than younger 
participants. Unlike older generations, younger participants 
grew up with treatment available and may therefore con-
sider it a given. One participant spontaneously mentioned 
his concern for the cost of new therapies specifically. Given 
that the costs of current treatment were important to most 
participants, it is probable that costs also play a role in deci-
sions about novel therapies. In the Netherlands, the cost of 
coagulation factor is covered by the healthcare system, but 
all participants in our sample were aware of the high costs 
and some even tried to save costs by avoiding self-infusion, 
even when they had a bleed. Possibly, recent media atten-
tion surrounding health technology assessments, pricing and 
reimbursement decisions for expensive drugs in rare diseases 
may have shaped participants’ opinions [26]. Costs of future 
novel treatment options, for example of gene therapy, are 
still unknown, making this difficult to address in patient-cli-
nician interactions. However, it may be of value to patients if 
healthcare providers are able to share what they know about 
the costs of current and future treatments.
Knowledge about which features of novel treatments are 
important, including real and perceived risks such as patho-
gen transmission, may help the haemophilia treatment team 
tailor information provision and patient education efforts. 
To structure this information in these interactions, a shared 
decision-making tool may be used. An interactive digital 
platform may further personalise information provision. Our 
findings may serve as a starting point for the contents of 
a shared decision-making tool. We suggest to explore this 
further in focus groups of patients and caregivers of patients.
4.1  Strengths and Limitations
A strength of our study is that it included a variety of per-
spectives on new treatments, illustrated by quotes. We pur-
posively included people of different ages, including parents 
of young boys, and with varying involvement in the haemo-
philia community (active or no membership of the Neth-
erlands Haemophilia Society). This was done because we 
presumed differences in the knowledge of new treatments. 
We also considered it important to include parents of young 
boys with haemophilia to explore how they viewed treatment 
decisions for their sons. Although the disease context of 
mothers is different from that of patients, we included them 
because they are responsible for making treatment decisions 
on behalf of their sons. In line with previous research [8], the 
mothers in our sample were somewhat more hesitant than 
patients to switch to a new treatment. Our study adds that 
this was because they preferred to wait for more information 
to become available on the effectiveness of these treatments.
A potential limitation may be that the first six partici-
pants responded to an advertisement through the Nether-
lands Haemophilia Society and therefore may have been 
better informed and more interested than average to discuss 
their views on treatment. Therefore, to obtain perspectives 
of representatives of the complete haemophilia community, 
the next eight participants were approached through the out-
patient clinic at the Amsterdam University Medical Center. 
In both groups, participants knew about gene therapy and 
extended half-life products, but other options, such as by-
passing agents or other non-factor replacement treatments, 
were not mentioned.
A second limitation may be that participants could have 
expressed a more positive satisfaction with their current 
treatment than their true experience. Participants were inter-
viewed at their homes by two investigators relatively new to 
the field of haemophilia, and the experiences participants 
shared about their current treatment may have been more 
positive than what they would have shared with their own 
healthcare provider. However, our aim was not to elicit all 
possible problems participants may experience with their 
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current treatment, but to explore the factors that may play 
a role in patients’ and parents’ decisions about current and 
new treatment options.
Last, extended half-life products and non-factor replace-
ment products have become available in the past 2 years. It 
is possible that participants are now better informed about 
these novel therapies than they were at the time of their 
interviews. Participants’ perceptions may have changed as 
a result of this: acceptability of newer products may have 
increased. However, we believe that many of the concerns 
expressed may be applicable to decisions on any type of 
treatment product switch, regardless of whether the switch 
is made to a novel therapy or an existing treatment.
5  Conclusions
New treatments for haemophilia are becoming available in 
the next few years, increasing the number of options patients 
and providers can choose from. Patients have a voice in these 
decisions. We confirmed previously identified barriers and 
facilitators that play a role in making these decisions, and 
added that costs of treatment may play a role. It is important 
for haemophilia treatment teams to be aware of these fac-
tors in providing information to facilitate shared decision 
making.
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